MSTN and chronic kidney disease: In this study, we sought to investigate the therapeutic potential of KMM001, an 18-mer chimeric ASO against the MSTN gene (in the form of a novel myostatin-specific inhibitor synthesized by KNC Laboratories Co, Ltd. (Kobe, Japan)), in boosting muscular development, strength, and efficacy within an animal model of CKD.